NWF Advisory Services Inc. Has $469,000 Position in GRAIL, Inc. $GRAL

NWF Advisory Services Inc. lessened its stake in GRAIL, Inc. (NASDAQ:GRAL) by 58.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,081 shares of the company’s stock after selling 12,989 shares during the period. NWF Advisory Services Inc.’s holdings in GRAIL were worth $469,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of GRAIL by 159.1% in the third quarter. JPMorgan Chase & Co. now owns 206,120 shares of the company’s stock valued at $12,188,000 after purchasing an additional 126,576 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in GRAIL by 154,361.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 91,132 shares of the company’s stock worth $7,531,000 after buying an additional 91,073 shares in the last quarter. WIM INVESTMENT MANAGEMENT Ltd increased its holdings in GRAIL by 68.9% in the 4th quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 106,400 shares of the company’s stock valued at $9,107,000 after buying an additional 43,400 shares during the period. Vanguard Group Inc. increased its holdings in GRAIL by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after buying an additional 163,790 shares during the period. Finally, Pictet Asset Management Holding SA increased its holdings in GRAIL by 1,036.8% in the 4th quarter. Pictet Asset Management Holding SA now owns 40,926 shares of the company’s stock valued at $3,585,000 after buying an additional 37,326 shares during the period.

Insider Activity at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the sale, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.83% of the company’s stock.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Several plaintiff firms reiterated class-action and lead-plaintiff deadlines for investors who bought GRAL shares between May 13, 2025 and February 19, 2026, keeping the lawsuit in focus. Article Title
• Neutral Sentiment: The filings reinforce that the suit centers on alleged misrepresentations about NHS-Galleri trial results and a major post-news stock decline, which remains the main investor concern. Article Title
• Negative Sentiment: The concentration of lawsuits and deadline reminders increases legal overhang and could keep pressure on GRAIL shares until more clarity emerges on the case. Article Title

GRAIL Price Performance

Shares of GRAL opened at $73.12 on Wednesday. The company has a market capitalization of $3.14 billion, a P/E ratio of -7.05 and a beta of 3.22. GRAIL, Inc. has a one year low of $29.95 and a one year high of $118.84. The business’s 50 day simple moving average is $65.01 and its 200-day simple moving average is $69.58.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The firm had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. On average, sell-side analysts anticipate that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GRAL has been the subject of a number of analyst reports. Robert W. Baird set a $70.00 price objective on shares of GRAIL in a report on Wednesday, May 6th. Mizuho began coverage on shares of GRAIL in a research report on Friday, April 10th. They issued a “neutral” rating and a $58.00 price target for the company. Guggenheim cut their price target on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Piper Sandler lifted their price objective on GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $67.00.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.